12歳以上の喘息患者を対象に、噴射剤HFA-152aまたはHFA-134aを含むMDIを介して投与されたサルブタモールによる3カ月間の治療の安全性と忍容性を評価および比較する研究
噴射剤 HFA-152a または参照 HFA-134a を含む定量吸入器を介して投与された場合のサルブタモール救済薬の長期安全性を評価するための無作為化二重盲検並行グループ多施設研究
The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged >=18 years with asthma
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
California
-
North Hollywood、California、アメリカ、91606-3287
- GSK Investigational Site
-
San Mateo、California、アメリカ、94403
- GSK Investigational Site
-
-
Florida
-
Aventura、Florida、アメリカ、33180
- GSK Investigational Site
-
Clearwater、Florida、アメリカ、33756
- GSK Investigational Site
-
DeLand、Florida、アメリカ、32720
- GSK Investigational Site
-
Miami、Florida、アメリカ、33173
- GSK Investigational Site
-
Miami、Florida、アメリカ、33144
- GSK Investigational Site
-
Miami、Florida、アメリカ、33155
- GSK Investigational Site
-
Naples、Florida、アメリカ、34102
- GSK Investigational Site
-
Plantation、Florida、アメリカ、33317
- GSK Investigational Site
-
Winter Park、Florida、アメリカ、32789-3385
- GSK Investigational Site
-
-
Georgia
-
Rincon、Georgia、アメリカ、31326-5131
- GSK Investigational Site
-
Stonecrest、Georgia、アメリカ、30038
- GSK Investigational Site
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40217
- GSK Investigational Site
-
Owensboro、Kentucky、アメリカ、42301
- GSK Investigational Site
-
-
Massachusetts
-
Fall River、Massachusetts、アメリカ、02723-1511
- GSK Investigational Site
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55402-2508
- GSK Investigational Site
-
Minneota、Minnesota、アメリカ、56001
- GSK Investigational Site
-
-
Mississippi
-
Olive Branch、Mississippi、アメリカ、38654
- GSK Investigational Site
-
-
Missouri
-
Columbia、Missouri、アメリカ、65203
- GSK Investigational Site
-
-
Nevada
-
Henderson、Nevada、アメリカ、89052-5015
- GSK Investigational Site
-
-
New Jersey
-
Jersey City、New Jersey、アメリカ、07306
- GSK Investigational Site
-
Riverdale、New Jersey、アメリカ、07457
- GSK Investigational Site
-
-
New York
-
Brooklyn、New York、アメリカ、11220
- GSK Investigational Site
-
-
North Carolina
-
Asheville、North Carolina、アメリカ、28803
- GSK Investigational Site
-
Winston-Salem、North Carolina、アメリカ、27104
- GSK Investigational Site
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45231
- GSK Investigational Site
-
Dublin、Ohio、アメリカ、43016
- GSK Investigational Site
-
-
Oregon
-
Medford、Oregon、アメリカ、97504
- GSK Investigational Site
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19107
- GSK Investigational Site
-
Pittsburgh、Pennsylvania、アメリカ、15241
- GSK Investigational Site
-
Pottstown、Pennsylvania、アメリカ、19464-3241
- GSK Investigational Site
-
-
South Carolina
-
Rock Hill、South Carolina、アメリカ、29732
- GSK Investigational Site
-
Spartanburg、South Carolina、アメリカ、29303
- GSK Investigational Site
-
Spartanburg、South Carolina、アメリカ、29303-4225
- GSK Investigational Site
-
Union、South Carolina、アメリカ、29379-7409
- GSK Investigational Site
-
-
Texas
-
Sugar Land、Texas、アメリカ、77479
- GSK Investigational Site
-
Tomball、Texas、アメリカ、77375-3332
- GSK Investigational Site
-
-
-
-
-
Buenos Aires、アルゼンチン、C1425BEN
- GSK Investigational Site
-
Buenos Aires、アルゼンチン、C1426ABP
- GSK Investigational Site
-
Buenos Aires、アルゼンチン、C1425AZE
- GSK Investigational Site
-
La Plata、アルゼンチン、1900
- GSK Investigational Site
-
Mendoza、アルゼンチン、M5500CCG
- GSK Investigational Site
-
-
-
-
-
Bebington、イギリス、CH63 9JP
- GSK Investigational Site
-
Cambridgeshire、イギリス、CB7 5JD
- GSK Investigational Site
-
Corby、イギリス、NN17 2UR
- GSK Investigational Site
-
Greater Manchester、イギリス、OL6 6HD
- GSK Investigational Site
-
Guisborough、イギリス、TS14 7DJ
- GSK Investigational Site
-
Hounslow、イギリス、TW3 3EL
- GSK Investigational Site
-
Rhyl、イギリス、LL18 4HZ
- GSK Investigational Site
-
Uttoxeter、イギリス、ST14 5JX
- GSK Investigational Site
-
-
-
-
-
Cagliari、イタリア、09042
- GSK Investigational Site
-
Florence、イタリア、50134
- GSK Investigational Site
-
Foggia、イタリア、71100
- GSK Investigational Site
-
Milan、イタリア、20162
- GSK Investigational Site
-
Naples、イタリア、80131
- GSK Investigational Site
-
Padova、イタリア、35128
- GSK Investigational Site
-
Torino、イタリア、10128
- GSK Investigational Site
-
Tradate VA、イタリア、21100
- GSK Investigational Site
-
Verona、イタリア、37134
- GSK Investigational Site
-
-
RM
-
Roma、RM、イタリア、00161
- GSK Investigational Site
-
-
-
-
New South Wales
-
Botany、New South Wales、オーストラリア、2019
- GSK Investigational Site
-
Coffs Harbour、New South Wales、オーストラリア、2450
- GSK Investigational Site
-
Kanwal、New South Wales、オーストラリア、2259
- GSK Investigational Site
-
-
Western Australia
-
Spearwood、Western Australia、オーストラリア、6163
- GSK Investigational Site
-
-
-
-
Ontario
-
Ajax、Ontario、カナダ、L1S 2J5
- GSK Investigational Site
-
Brampton、Ontario、カナダ、L6T 0G1
- GSK Investigational Site
-
Ottawa、Ontario、カナダ、K1H 1E4
- GSK Investigational Site
-
Toronto、Ontario、カナダ、M9V 4B4
- GSK Investigational Site
-
Windsor、Ontario、カナダ、N8X 2G1
- GSK Investigational Site
-
-
Quebec
-
Québec、Quebec、カナダ、G1V 4W2
- GSK Investigational Site
-
Québec、Quebec、カナダ、G1W 4R4
- GSK Investigational Site
-
-
-
-
-
Athens、ギリシャ、15669
- GSK Investigational Site
-
Larissa、ギリシャ、41110
- GSK Investigational Site
-
Thessaloniki、ギリシャ、57010
- GSK Investigational Site
-
-
-
-
-
Barcelona、スペイン、08017
- GSK Investigational Site
-
Barcelona、スペイン、08540
- GSK Investigational Site
-
Benalmádena、スペイン、29631
- GSK Investigational Site
-
Madrid、スペイン、28041
- GSK Investigational Site
-
Madrid、スペイン、28040
- GSK Investigational Site
-
Madrid、スペイン、28031
- GSK Investigational Site
-
Marbella、スペイン、29603
- GSK Investigational Site
-
Pozuelo de AlarcOn Madr、スペイン、28223
- GSK Investigational Site
-
-
-
-
-
Pathum Thani、タイ、12120
- GSK Investigational Site
-
-
-
-
-
Panama City、パナマ
- GSK Investigational Site
-
Panama City、パナマ、7099
- GSK Investigational Site
-
Panama City、パナマ、7002
- GSK Investigational Site
-
-
-
-
-
Iloilo City、フィリピン、5000
- GSK Investigational Site
-
-
-
-
-
Amiens、フランス、80054
- GSK Investigational Site
-
Argenteuil、フランス、95100
- GSK Investigational Site
-
Créteil、フランス、94010
- GSK Investigational Site
-
Poitiers、フランス、86021
- GSK Investigational Site
-
Pontoise、フランス、95303
- GSK Investigational Site
-
Strasbourg、フランス、67091
- GSK Investigational Site
-
-
-
-
-
Bialystok、ポーランド、15-010
- GSK Investigational Site
-
Bielsko-Biala、ポーランド、43-300
- GSK Investigational Site
-
Chorzów、ポーランド、41-500
- GSK Investigational Site
-
Elblag、ポーランド、82-300
- GSK Investigational Site
-
Katowice、ポーランド、40-600
- GSK Investigational Site
-
Ostrowiec Świętokrzyski、ポーランド、27-400
- GSK Investigational Site
-
Płock、ポーランド、09-407
- GSK Investigational Site
-
Tarnów、ポーランド、33-100
- GSK Investigational Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Participant of ≥18 years of age at the time of signing the informed consent or written informed consent is obtained from each study participant's legal guardian.
-
Asthma for ≥ 6 months, defined as:
-
Documented history of asthma, as defined by Global Initiative for Asthma (GINA) (GINA, 2023]
-
Receiving one of the following asthma treatments, at a stable dose (applicable to daily Inhaled corticosteroid (ICS), ICS/Long-acting bronchodilator (LABA), and ICS/LABA/Long-acting muscarinic antagonist [LAMA]), for at least 12 weeks prior to the screening visit, with treatment that is anticipated to remain stable for the duration of the study:
- Short-Acting Beta-2-Adrenoreceptor Agonists (SABA) used as needed for asthma symptoms
- Daily maintenance low to medium dose Inhaled corticosteroid (ICS) (low to medium dose ICS defined as 100-500 μg/day fluticasone propionate or equivalent as defined in the 2023 GINA guidelines [GINA, 2023], plus Short-Acting Beta-2-Adrenoreceptor Agonists (SABA), which is anticipated to remain stable for the duration of the study.
- Daily maintenance low to medium dose ICS/ Long-acting bronchodilator (LABA) (low to medium dose ICS defined as 100-500 μg/day fluticasone propionate or equivalent as defined in the GINA guidelines [GINA, 2023] plus SABA, which is anticipated to remain stable for the duration of the study.
- Daily maintenance ICS/LABA/LAMA (low to medium dose ICS defined as 100-500 µg/day fluticasone propionate or equivalent as defined in the GINA guidelines [GINA, 2023] plus SABA, which is anticipated to remain stable for the duration of the study.
- Participants who utilize combination budesonide/formoterol as reliever therapy, whether or not this is in addition to a SABA - are not eligible for screening.
- Participants who utilize ICS/SABA combination therapy as reliever therapy, in addition to low to medium dose ICS or ICS/LABA as maintenance, are only eligible if they agree to discontinue their ICS/SABA inhaler for the duration of the study (screening through follow-up).
-
-
Severity of disease assessed by the investigator by baseline pre-bronchodilator Forced expiratory volume in 1 second (FEV1)
-
Asthma Control Status
-
Asthma Control Questionnaire (ACQ) 6 score <1.5 at screening
-
Asthma that has remained stable with no severe exacerbations in the last 6 months. Severe exacerbation defined as:
- Deterioration of asthma-requiring the use of systemic corticosteroids (tablets, suspension or injection), for at least 3 days, OR
- An inpatient hospitalization or Emergency Department (ED) visit because of asthma, requiring systemic corticosteroids.
-
-
Evidence of reversibility of disease: Airway reversibility is defined as ≥12 percent (%) and ≥200 milliliter (mL) increase in FEV1 within 20 to 60 minutes following up to 4 inhalations of albuterol/salbutamol aerosol.
-
Participants on as-needed SABA only, or daily maintenance ICS (plus as needed SABA):
-
With a documented history of reversibility (as defined above) within 2 years will meet this inclusion criterion. Pre- and post-bronchodilator measurements will still be collected at screening to characterize the degree of reversibility.
-
Who do not have a documented history of reversibility within the past 2 years will need to demonstrate reversibility during the screening period.
- SABA should be withheld for ≥6 hours
- Participants on daily maintenance ICS/LABA or ICS/LABA/LAMA:
-
-
Participants on daily maintenance ICS/LABA or ICS/LABA/LAMA:
-
Do not need to demonstrate reversibility in accordance with the above definition during the screening period. A reversibility maneuver will be performed to characterize the degree of post-bronchodilator change.
- SABA should be withheld for ≥6 hours
- LABA- and LAMA-containing medications should be withheld for >=24 hours for the characterization of post-bronchodilator change.
-
Participants should be able to withhold SABA for ≥6 hours and LABA-/ LAMA containing medications for ≥24 hours for the purposes of performing screening spirometry.
Exclusion Criteria:
- A history of life-threatening asthma or asthma that is unstable in the opinion of the investigator.
- Other significant pulmonary diseases to include (but not limited to): pneumothorax, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, tuberculosis or other respiratory abnormalities other than asthma.
- Respiratory Infection: Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of screening that led to a change in asthma management, OR in the opinion of the Investigator, is expected to affect the participant's asthma status, OR the participant's ability to participate in the study.
- Asthma Exacerbation: Any severe asthma exacerbation within 6 months prior to screening.
- Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) Biologic/immunosuppressive therapies used for the treatment of respiratory diseases during the 6 months, or 5 half-lives-whichever is longer-prior to start of the study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Salbutamol HFA-152a MDI
Participants with asthma received inhalation of 200 microgram (ug) (2*100 ug) or as needed up to maximum 800 µg once daily Salbutamol HFA-152a (Test) via metered dose inhaler (MDI) suspension at 30 second intervals per actuation. Participants attended 5 On-treatment visits at Weeks 0 (Day 1), 1, 4, 8 & 12 and a Follow-up visit at Week 13. |
100 μg (ex-valve) at 30-second intervals per actuation |
|
アクティブコンパレータ:Salbutamol HFA-134a MDI
Participants with asthma received inhalation of 200 microgram (ug) (2*100 ug) once daily plus as needed up to maximum 800 of µg Salbutamol HFA-134a (Reference) via metered dose inhaler (MDI) suspension at 30 second intervals per actuation. Participants attended 5 On-treatment visits at Weeks 0 (Day 1), 1, 4, 8 & 12 and a Follow-up visit at Week 13. |
100 microgram (μg) (ex-valve) at 30-second intervals per actuation |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Adverse Events (AEs) During Run-in Period
時間枠:From Week -1 up to randomization (Day 1) during Run-in period
|
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system. |
From Week -1 up to randomization (Day 1) during Run-in period
|
|
Number of Participants With Adverse Events (AEs) During Treatment Period
時間枠:From randomization (Day 1) up to Week 13 (Follow up) during treatment period
|
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system. |
From randomization (Day 1) up to Week 13 (Follow up) during treatment period
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Serious Adverse Events (SAEs) During Run-in Period
時間枠:From Week -1 up to randomization (Day 1) during Run-in period
|
SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy), Is a suspected transmission of any infectious agent via an authorized medicinal product, other situations judged by physician, is associated with liver injury and impaired liver function. SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system. |
From Week -1 up to randomization (Day 1) during Run-in period
|
|
Number of Participants With Serious Adverse Events (SAEs) During Treatment Period
時間枠:From randomization (Day 1) up to Week 13 (Follow up) during treatment period
|
SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy), Is a suspected transmission of any infectious agent via an authorized medicinal product, other situations judged by physician, is associated with liver injury and impaired liver function. SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system. |
From randomization (Day 1) up to Week 13 (Follow up) during treatment period
|
|
Absolute Values of Minimum Serum Potassium
時間枠:Up to Week 13 (Follow up)
|
Blood samples were collected to analyze minimum serum potassium. |
Up to Week 13 (Follow up)
|
|
Absolute Values of Serum Potassium at Each Assessed Visit
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the serum potassium. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline (CFB) in Serum Potassium at Each Assessed Visit
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the serum potassium. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Hematology Parameter: Erythrocytes
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Hematology Parameter: Erythrocytes
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Hematology Parameter: Mean Corpuscular Volume (MCV)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: MCV. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Hematology Parameter: MCV
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: MCV. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: MCH. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Hematology Parameter: MCH
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: MCH. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Hematology Parameter: Percentage of Reticulocytes
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Percentage of Reticulocytes. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Hematology Parameter: Percentage of Reticulocytes
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Percentage of Reticulocytes. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and platelets. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and platelets. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Hematology Parameter: Hemoglobin (Hgb)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Hgb. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Hematology Parameter: Hemoglobin (Hgb)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Hgb. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Hematology Parameter: Hematocrit
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Hematology Parameter: Hematocrit
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Clinical Chemistry Parameters: Calcium, Potassium, Sodium, Urea and Glucose (Non-fasting)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the Clinical Chemistry parameters: Calcium, Potassium, Sodium, Urea and Glucose (non-fasting). Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Clinical Chemistry Parameters: Calcium, Potassium, Sodium, Urea and Glucose (Non-fasting)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the Clinical Chemistry parameters: Calcium, Potassium, Sodium, Urea and Glucose (non-fasting). Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Clinical Chemistry Parameters: Direct Bilirubin Total Bilirubin and Creatinine
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the Clinical Chemistry parameters: Direct Bilirubin Total Bilirubin and Creatinine. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Clinical Chemistry Parameters: Direct Bilirubin Total Bilirubin and Creatinine
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the Clinical Chemistry parameters: Direct Bilirubin Total Bilirubin and Creatinine. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Phosphokinase (CPK)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the Clinical Chemistry Parameters: ALP, ALT, AST and CPK. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Phosphokinase (CPK)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the Clinical Chemistry Parameters: ALP, ALT, AST and CPK. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Value of Urinalysis Parameter: Potential of Hydrogen (pH)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Urine samples were collected to analyze the pH. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Urinalysis Parameter: Potential of Hydrogen (pH)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Urine samples were collected to analyze the pH. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Value of Urinalysis Parameter: Specific Gravity
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Urine samples were collected to analyze the Specific Gravity. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Urinalysis Parameter: Specific Gravity
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Urine samples were collected to analyze the Specific Gravity. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Number of Participants With Worst-case Urinalysis Results Post-baseline Relative to Baseline Urinalysis Dipstick Results: Occult Blood, Protein, Urobilinogen, Bilirubin, Glucose, Ketones, Leukocyte Esterase and Nitrite
時間枠:Up to Week 13 (Follow up)
|
Urinalysis parameters were assessed using standard Urinalysis dipsticks and categorized according to the semi-quantitative scale provided by the test strip manufacturer (e.g.,negative, trace, 1+,2+,3+,where applicable). For each parameter, worsening from baseline was defined as a shift from a lower category (Increased to TRACE & Non-hemolyzed TRACE), to a higher category (Increased to 1+, 2+, 3+, 4+, or 1, 2,4, 8 mg/dL & hemolyzed TRACE), indicating a greater degree of abnormality. The worst post-baseline category observed during the study was compared with the baseline category to derive a worst-case post-baseline change classification. Participants were categorized according to the magnitude of worsening observed (e.g.,No Change/Decreased, Increase to TRACE, Increase to 1+, Increase to 2+, etc., as applicable for the parameter assessed). Values that trend towards 'normal' or a lower category (i.e. from 2+ to 1+) indicates a shift towards /return to a negative result. |
Up to Week 13 (Follow up)
|
|
Absolute Values for Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
SDP and DBP measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline in Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
SBP and DBP measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values for Vital Signs: Pulse Rate
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Pulse rate measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline in Vital Signs: Pulse Rate
時間枠:Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Pulse rate measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values for 12 Lead Electrocardiograms (ECGs) in QT Interval Corrected by Fridericia's Formula (QTcF)
時間枠:Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
A standard 12-lead ECG was obtained using an ECG machine that automatically measures QTcF intervals. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for QTc interval to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). |
Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline for 12 Lead ECGs in QTcF
時間枠:Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
A standard 12-lead ECG was obtained using an ECG machine that automatically measures QTcF intervals. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for QTc interval to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values for Heart Rate
時間枠:Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
A standard 12-lead ECG was obtained using an ECG machine that automatically measures HR. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for HR to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). |
Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline in Heart Rate
時間枠:Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
A standard 12-lead ECG was obtained using an ECG machine that automatically measures HR. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for HR to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score
時間枠:Baseline (Day 1, pre-dose) and Week 12
|
The ACQ-6 measures 6 attributes of asthma control and are measured with a participant completed questionnaire. ACQ-6 consists of six questionnaires about the frequency and/or severity of symptoms (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath, wheeze and rescue medication use). Each question was scored from zero (no impairment/limitation) to six (total impairment/ limitation). The ACQ-6 score is calculated as the mean of the scores from the six questionnaire items. ACQ-6 score ranges from 0 to 6 with higher scores indicate greater impairment. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose) and Week 12
|
|
Change From Baseline for Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
時間枠:Baseline (Day 1, pre-dose) and Week 12
|
Forced Expiratory Volume in one second (FEV1) is defined as the volume of air forcibly exhaled in one second. Pre-bronchodilator FEV1 measurements were taken by spirometry. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose) and Week 12
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:GSK Clinical Trials、GlaxoSmithKline
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 220735
- 2023-509001-76-00 (その他の識別子:EU CT Number)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
IPD 共有時間枠
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD 共有アクセス基準
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。